View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
September 7, 2018updated 12 Jul 2022 1:12pm

argenx begins dosing in Phase III myasthenia gravis trial

Biotechnology company argenx has started dosing patients in a Phase III clinical trial of its drug candidate efgartigimod (ARGX-113) to treat generalised myasthenia gravis (gMG).

Biotechnology company argenx has started dosing patients in a Phase III clinical trial of its drug candidate efgartigimod (ARGX-113) to treat generalised myasthenia gravis (gMG).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Efgartigimod is an antibody fragment being developed to help patients suffering from severe autoimmune diseases characterised by high-pathogenic immunoglobulin G (IgG) antibody levels.

The therapeutic is designed to degrade circulating autoimmune antibodies responsible for the disease.

The randomised, double-blind, placebo-controlled, multi-centre, global Phase III trial will assess the efficacy of a 10mg/kg intravenous efgartigimod dose in around 150 subjects over 26 weeks.

Both AChR auto-antibody positive and negative patients with generalised myasthenia gravis driven by MuSK and LRP4 auto-antibodies will be recruited across North America, Europe and Japan.

“The dosing of the first patient represents an important milestone in advancing efgartigimod towards registration with the hopes of providing more therapeutic options for gMG patients globally.”

The primary endpoint of the Phase III trial is efficacy measured using the Myasthenia Gravis Activities of Daily Living (MG-ADL) score.

In addition, the trial will monitor secondary and other endpoints such as additional efficacy, safety, tolerability, quality of life and impact on normal everyday activities.

Participants in this study will be given an option to enrol into an open-label extension trial for one year.

argenx chief medical officer Nicolas Leupin said: “The dosing of the first patient represents an important milestone in advancing efgartigimod towards registration with the hopes of providing more therapeutic options for gMG patients globally.

“With planned enrolment of 150 patients, this will be the broadest trial of its kind in gMG, and the first to address both acetylcholine receptor (AChR) autoantibody positive as well as AChR autoantibody negative patients like those with MuSK MG.”

A previous Phase II trial demonstrated clinical improvement in generalised myasthenia gravis patients treated with efgartigimod for 11 weeks, when compared to placebo.

The drug candidate was found to be well-tolerated with mild adverse events (AEs).

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Topics in this article: , ,
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena